ATE374624T1 - Verfahren zur stabilisierung von ungeordnetem cefovecin-natriumsalz - Google Patents
Verfahren zur stabilisierung von ungeordnetem cefovecin-natriumsalzInfo
- Publication number
- ATE374624T1 ATE374624T1 AT05718419T AT05718419T ATE374624T1 AT E374624 T1 ATE374624 T1 AT E374624T1 AT 05718419 T AT05718419 T AT 05718419T AT 05718419 T AT05718419 T AT 05718419T AT E374624 T1 ATE374624 T1 AT E374624T1
- Authority
- AT
- Austria
- Prior art keywords
- sodium salt
- stabilizing
- disordered
- cefovecin sodium
- cefovecin
- Prior art date
Links
- QRIBXVGHDLFNNE-BMCBYEKFSA-M sodium;(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-3-[(2s)-oxolan-2-yl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1[C@@H]1CCCO1 QRIBXVGHDLFNNE-BMCBYEKFSA-M 0.000 title abstract 2
- 230000000087 stabilizing effect Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cephalosporin Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56437204P | 2004-04-22 | 2004-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE374624T1 true ATE374624T1 (de) | 2007-10-15 |
Family
ID=35033440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05718419T ATE374624T1 (de) | 2004-04-22 | 2005-04-11 | Verfahren zur stabilisierung von ungeordnetem cefovecin-natriumsalz |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20080096858A1 (de) |
| EP (1) | EP1740214B1 (de) |
| JP (1) | JP2007533724A (de) |
| AT (1) | ATE374624T1 (de) |
| BR (1) | BRPI0509992A (de) |
| CA (1) | CA2563665A1 (de) |
| DE (1) | DE602005002742T2 (de) |
| ES (1) | ES2292122T3 (de) |
| MX (1) | MXPA06012215A (de) |
| WO (1) | WO2005102274A2 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2106788A1 (de) * | 2008-04-04 | 2009-10-07 | Ipsen Pharma | Flüssige und lyophilisierte Formulierungen |
| CN105254648B (zh) * | 2015-11-13 | 2018-04-03 | 广东温氏大华农生物科技有限公司 | 一种头孢维星及其钠盐的合成方法 |
| CN112843003A (zh) * | 2021-03-25 | 2021-05-28 | 海南海灵化学制药有限公司 | 一种注射用拉氧头孢钠的冻干粉及其冻干工艺 |
| CN115737573B (zh) * | 2022-11-30 | 2024-02-20 | 杭州沐源生物医药科技有限公司 | 一种注射用拉氧头孢钠冻干粉剂及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4029655A (en) * | 1975-04-11 | 1977-06-14 | Eli Lilly And Company | Method of preparing stable sterile crystalline cephalosporins for parenteral administration |
| US4002748A (en) * | 1976-01-19 | 1977-01-11 | Eli Lilly And Company | Method of preparing sterile essentially amorphous cefazolin for reconstitution for parenteral administration |
| US6001997A (en) * | 1990-07-24 | 1999-12-14 | Bateson; John Hargreaves | Cephalosporins and homologues, preparations and pharmaceutical compositions |
| US6020329A (en) * | 1990-07-24 | 2000-02-01 | Pzifer Inc. | Cephaloporins and homologues, preparations and pharmaceutical compositions |
| GB9726343D0 (en) * | 1997-12-13 | 1998-02-11 | Auffret Anthony | The use of excipients to accelerate freeze-drying |
| US6284282B1 (en) * | 1998-04-29 | 2001-09-04 | Genentech, Inc. | Method of spray freeze drying proteins for pharmaceutical administration |
| US7378408B2 (en) * | 2001-11-30 | 2008-05-27 | Pfizer Inc. | Methods of treatment and formulations of cephalosporin |
| BR0215070A (pt) * | 2001-12-21 | 2004-11-09 | Pfizer Prod Inc | Métodos de tratamento de infecções bacterianas em cães e gatos |
| US20040214753A1 (en) * | 2003-03-20 | 2004-10-28 | Britten Nancy Jean | Dispersible pharmaceutical composition for treatment of mastitis and otic disorders |
| EP1656159A2 (de) * | 2003-07-31 | 2006-05-17 | Pharmacia & Upjohn Company LLC | Dispergierbare pharmazeutische zusammensetzung zur behandlung von mastitis und ohrerkrankungen |
-
2005
- 2005-04-11 JP JP2007508993A patent/JP2007533724A/ja not_active Withdrawn
- 2005-04-11 EP EP05718419A patent/EP1740214B1/de not_active Expired - Lifetime
- 2005-04-11 AT AT05718419T patent/ATE374624T1/de not_active IP Right Cessation
- 2005-04-11 WO PCT/IB2005/000955 patent/WO2005102274A2/en not_active Ceased
- 2005-04-11 MX MXPA06012215A patent/MXPA06012215A/es active IP Right Grant
- 2005-04-11 US US11/587,032 patent/US20080096858A1/en not_active Abandoned
- 2005-04-11 ES ES05718419T patent/ES2292122T3/es not_active Expired - Lifetime
- 2005-04-11 DE DE602005002742T patent/DE602005002742T2/de not_active Expired - Fee Related
- 2005-04-11 CA CA002563665A patent/CA2563665A1/en not_active Abandoned
- 2005-04-11 BR BRPI0509992-7A patent/BRPI0509992A/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA06012215A (es) | 2007-04-19 |
| WO2005102274A3 (en) | 2006-03-30 |
| DE602005002742T2 (de) | 2008-01-24 |
| WO2005102274A2 (en) | 2005-11-03 |
| ES2292122T3 (es) | 2008-03-01 |
| EP1740214B1 (de) | 2007-10-03 |
| CA2563665A1 (en) | 2005-11-03 |
| DE602005002742D1 (de) | 2007-11-15 |
| EP1740214A2 (de) | 2007-01-10 |
| JP2007533724A (ja) | 2007-11-22 |
| BRPI0509992A (pt) | 2007-10-16 |
| US20080096858A1 (en) | 2008-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1933862A4 (de) | Verfahren und zusammensetzungen zur oralen verabreichung von proteinen | |
| DE602004018714D1 (de) | Verfahren zur Bereitstellung von zweiteiligen, selbstklebenden Dentalmassen | |
| DE602004026698D1 (de) | Verfahren zur gemeinsmen benutzung von multimedia-daten | |
| DE602004026576D1 (de) | Verbessertes verfahren zur herstellung vom rosuvastatin calcium salz | |
| ATE453630T1 (de) | Verfahren zur herstellung von 2-aminothiazol-5- aromatischen carbonsäureamiden als kinaseinhibitoren | |
| EA200870217A1 (ru) | 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции | |
| EP1951232A4 (de) | Verfahren zur reduzierung von alkohol-induziertem dosis-dumping für orale opioid-dosierformen mit verzögerter freisetzung | |
| NO20090175L (no) | Stabile laquinimod sammensetninger | |
| DE602005003293D1 (de) | Verfahren zur Markierung von pharmazeutischen Produkten | |
| DE602005026556D1 (de) | Zusammensetzung zur proteasomhemmung | |
| BE2014C011I2 (fr) | Administration d'inhibiteurs de dipeptidyl peptidase | |
| UA96565C2 (ru) | Пиридильные ингибиторы хеджхоговской передачи сигнала | |
| DE50311676D1 (de) | Vorrichtung zur elastischen stabilisierung von wirbelkörpern | |
| TN2010000203A1 (en) | Beta-lactamase inhibitors | |
| ATE459621T1 (de) | Benzisoxazolpiperidinverbindungen und verfahren zu deren anwendung | |
| EP2055677A4 (de) | Verfahren zur herstellung von bandförmigen re-basis-(123)-supraleitern | |
| DE602006000874D1 (de) | Wässrige Zusammensetzungen enthaltend Salze von Perfluoropolyether Dicarbonsäuren zur ölabstossenden Papierleimung | |
| ATE409470T1 (de) | Pharmazeutische zusammensetzungen mit malonamid- derivaten zur verringerung der talg-produktion | |
| ATE336464T1 (de) | Verfahren zur aufreinigung von blausäure | |
| ATE374624T1 (de) | Verfahren zur stabilisierung von ungeordnetem cefovecin-natriumsalz | |
| ATE471326T1 (de) | Substituierte thienopyrrolcarbonsäureamide, pyrrolothiazolcarbonsäureamide und verwandte analoga als inhibitoren von caseinkinase-i- epsilon | |
| DE602006012761D1 (de) | Verfahren zur Identifizierung von Medikamenten, vor Verabreichung | |
| TW200604173A (en) | Novel compounds | |
| NO20091771L (no) | Ny krystall av (S)-(+)-2-(2-klorfenyl)-2-hydroksyetylkarbamat | |
| DE602005006550D1 (de) | Verfahren zur aufreinigung von mesotrion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |